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Abstract
Background: Effective prevention of type 2 diabetes (T2D) requires early identification of high-risk individuals who
might benefit from intervention. We sought to determine whether low serum testosterone, a novel risk factor for
T2D in men, adds clinically meaningful information beyond current T2D risk models.
Methods: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) study population consists of
2563 community-dwelling men aged 35–80 years in Adelaide, Australia. Of the MAILES participants, 2038 (80.0 %)
provided information at baseline (2002–2006) and follow-up (2007–2010). After excluding participants with
diabetes (n = 317), underweight (n = 5), and unknown BMI status (n = 11) at baseline; and unknown diabetes
status (n = 50) at follow-up; 1655 participants were followed for 5 years. T2D at baseline and follow-up was
defined by self-reported diabetes, or fasting plasma glucose (FPG) ≥7.0 mmol/L (126.1 mg/dL), or glycated
haemoglobin (HbA1c) ≥6.5 %, or diabetes medications. Risk models were tested using logistic regression
models. Sensitivity, specificity, positive predictive values (PPV) were used to identify the optimal cut-off point for
low serum testosterone for incident T2D and the area under the receiver operating characteristic (AROC) curve
was used to summarise the predictive power of the model. 15.5 % of men had at least one missing predictor
variable; addressed through multiple imputation.
Results: The incidence rate of T2D was 8.9 % (147/1655) over a median follow-up of 4.95 years (interquartile
range: 4.35-5.00). Serum testosterone level predicted incident T2D (relative risk 0.96 [95 % CI: 0.92,1.00], P = 0.032)
independent of current risk models including the AUSDRISK, but did not improve corresponding AROC
statistics. A cut-off point of <16 nmol/L for low serum testosterone, which classified about 43 % of men,
returned equal sensitivity (61.3 % [95 % CI: 52.6,69.4]) and specificity (58.3 % [95 % CI: 55.6,60.9) for predicting
T2D risk, with a PPV of 12.9 % (95 % CI: 10.4,15.8).
Conclusions: Low serum testosterone predicts an increased risk of developing T2D in men over 5 years
independent of current T2D risk models applicable for use in routine clinical practice. Screening for low
serum testosterone in addition to risk factors from current T2D risk assessment models or tools, including the
AUSDRISK, would identify a large subgroup of distinct men who might benefit from targeted preventive
interventions.
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Key messages
 Serum testosterone predicts risk of T2D in men
independent of current risk assessment models or
tools
 A cut-off point of <16 nmol/L for low serum
testosterone was optimal for predicting T2D risk
in men
 Over 40 % of men had low serum testosterone
(<16 nmol/L)
 Additional screening for low serum testosterone
would identify a large group of distinct men who
might benefit from targeted preventive interventions
Background
Type 2 diabetes (T2D) accounts for at least 90 % of
all cases of diabetes and is an increasingly prevalent
and debilitating disease [1]. Diabetes is currently
ranked the 14th leading cause of global disease bur-
den, and has moved up several places since 1990 [2].
The International Diabetes Federation estimates that
387 million people worldwide had diabetes in 2014,
and by 2035 this figure will rise to 592 million [1].
Preventing the rising prevalence of T2D in high-
income countries like Australia, where healthcare ex-
penditure for diabetes is among the highest in the
world [1], could yield significant health and economic
benefits [3].
It is generally accepted that people with diagnosed
T2D have progressed from ‘pre-diabetes’; an intermedi-
ate stage of impaired glucose regulation defined by im-
paired fasting glucose (IFG) and/or impaired glucose
tolerance (IGT) [4]. The prevalence of pre-diabetes
could be as high as 20 to 30 % in high-income countries
[5, 6]. Progression from pre-diabetes to T2D is likely ex-
plained by non-modifiable risk factors including older
age, male gender, ethnicity, and urbanisation [1]; as well
as modifiable risk factors including smoking, obesity,
unhealthy diet and physical activity behaviours [6–9].
Effective lifestyle programs targeting modifiable risk fac-
tors in people with pre-diabetes may delay or prevent
the onset of T2D. Indeed, large-scale trials from Finland
[10], China [11], and the United States [12] showed that
lifestyle intervention can effectively halve the risk of de-
veloping T2D in people with pre-diabetes over three to
six years.
Effective prevention of T2D requires early identifica-
tion of high-risk individuals who might benefit from
intervention. Screening for T2D risk factors can be cost-
effective, especially when followed by lifestyle interven-
tion [13]. There are at least seven diabetes risk models
or scoring systems (often called ‘risk assessment tools’)
with potential adaptation for use in routine clinical prac-
tice [14]. However, these tools may need to be updated
for novel biomarkers that have emerged since these risk
models were published.
Evidence from observational studies suggests that low
endogenous testosterone level may be a reversible risk
factor for T2D in men. For instance, a recent systematic
review with meta-analysis showed that men with testos-
terone levels >15.5 nmol/L have a 42 % reduced risk of
developing T2D compared with men with testosterone
levels ≤15.5 nmol/L [15]. Cross-sectional studies in
Australia show that a high proportion of men with T2D
have low testosterone level, and that low testosterone
level is inversely associated with glycaemia and insulin
resistance [16, 17]. On average, men with T2D and
metabolic syndrome (MetS) have a testosterone level
that is 2.6 nmol/L lower than controls [15, 18]. Sex hor-
mones may explain why men are more likely to develop
T2D than women, as shown in several T2D risk models
[19–21]. Therefore, the aim of this study was to deter-
mine whether low serum testosterone level adds clinic-
ally meaningful information beyond current T2D risk
models in men, to inform guidelines and clinical
practice.
Methods
Study design and setting
The Men Androgen Inflammation Lifestyle Environment
and Stress (MAILES) prospective cohort study was
established in 2009 to investigate the associations of
sex steroids, inflammation, environmental and psycho-
social factors with cardio-metabolic disease risk in
men [22]. The MAILES study population consists of
2563 community-dwelling men aged 35–80 years at
enrolment in Adelaide, Australia, from the harmonisation
of two cohort studies: all participants of the Florey
Adelaide Male Ageing Study (FAMAS) and a sub-set of
male participants of the North West Adelaide Health
Study (NWAHS). Written informed consent for participa-
tion in the study was obtained. The methods used in both
FAMAS [23, 24] and NWAHS [25, 26] including the val-
idity of subject selection for achieving a representative
population sample, have been described previously.
The FAMAS is a cohort study of 1195 randomly se-
lected men aged 35 years and over from the metropol-
itan region of Adelaide. Participants in the study were
required to be male, aged between 35 and 80 years at
the time of recruitment, living in the defined catchment
area of North and West Adelaide with a connected tele-
phone and number listed in the Electronic White Pages,
be willing and able to comply with the protocol and give
written, informed consent. Exclusion criteria were lim-
ited to living outside the catchment area and telephone
numbers that belonged to non-residential properties. Re-
cruiters were also instructed to exclude responders if
they were: (i) of insufficient mental or physical ability to
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understand the requirements of participation or ad-
equately participate; (ii) ill or otherwise incapacitated to
attend clinics; (iii) currently residing in an institution
(e.g. aged care facility) and (iv) non-English speaking.
Prior to the study commencing, approval for the re-
search was obtained from the Royal Adelaide Hospital
Research Ethics Committee and, where appropriate, the
Aboriginal Health Research Ethics Committee. The
FAMAS achieved an overall response rate of 45.1 % at
baseline (2002–05), and the sample was representative
of the male population for most key demographics [24].
The NWAHS is a cohort study of 4060 randomly
selected adults aged 18 years and over from the north-
west region of Adelaide. The sample was a randomly se-
lected population from the northern and western sub-
urbs of Adelaide. All households in the northern and
western areas of Adelaide with a telephone connected
and a telephone number listed in the Electronic White
Pages were eligible for selection in the study. Telephone
numbers that belonged to businesses, institutions and
residential care facilities were excluded from the sample.
However, people who had their own telephone number
and who were living in individual units attached to a
nursing home were eligible to participate. Within each
household, the person who had their birthday last and
was aged 18 years and over, was selected for interview
and invited to attend the clinic for a biomedical examin-
ation. The study excluded those people from a non-
English speaking background who could not communi-
cate sufficiently well with the telephone interviewer and
who could not answer questions at the initial recruit-
ment stage, although every effort was made to encourage
family members to assist in translating. The sub-set of
men aged 35 years and over was 1368. Prior to the study
commencing, approval for the research was obtained
from the North West Adelaide Health Service Ethics of
Human Research Committee and, where appropriate,
the Aboriginal Health Research Ethics Committee. The
NWAHS achieved an overall response rate of 49.6 % at
baseline (2000–03), and the sample was representative
of the population in terms of current smoking status,
body mass index (BMI), physical activity, overall health
status and proportions with current high blood pressure
and cholesterol readings [27].
Study population
The series of baseline data collections that form
MAILES Stage 1 include FAMAS from 2002–2005, and
NWAHS from 2004–2006. The series of follow-up data
collections that form MAILES Stage 2 include FAMAS
from 2007–2010, and NWAHS from 2008–2010. The
MAILES Stage 1 (baseline) sample was representative of
the population in the northern and western regions of
Adelaide [22]. A flow of the study population at each
stage of the MAILES Study, with the numbers of partici-
pants drawn from the respective stages of FAMAS and
NWAHS has been published [22]. Of the MAILES par-
ticipants, 2038 (80.0 %) provided information at both
stages of the study. Reasons for loss to follow-up (non-
respondents) include death (n = 99), too ill to participate
(n = 39), withdrew from the study (n = 141), were unable
to be tracked due to changes in contact details (n = 77),
and refused to take part in MAILES Stage 2 due to
work-related and personal reasons (n = 169). Non-
respondents in MAILES Stage 2 were more likely than
respondents to report diabetes, cardiovascular disease,
or depression, or to either not know or to not disclose
their chronic-disease status. For self-reported assess-
ments, non-respondents were more likely than respon-
dents to report that they had poorer health and were
current smokers or to not to provide information about
these factors. For measured assessments, non-respondents
were less likely than respondents to be overweight or
obese, or to have central adiposity. Finally, there were no
statistically significant differences between respondents
and non-responders in means for serum testosterone, fast-
ing plasma glucose (FPG), triglycerides, and high density
lipoprotein cholesterol (HDL-C).
After excluding participants with diabetes at baseline
(n = 317), underweight at baseline (n = 5), unknown BMI
at baseline (n = 11), and unknown diabetes status at
follow-up (n = 50), the final cohort sample studied con-
sisted of 1655 participants.
Primary outcome
T2D at baseline and follow-up was defined by self-reported
medically diagnosed diabetes, or FPG ≥7.0 mmol/L
(126.1 mg/dL), or glycated haemoglobin (HbA1c) ≥6.5 %
according to the American Diabetes Association criteria
[28], or prescriptions for medications used in diabetes
based on the Anatomical Therapeutic Chemical classifica-
tion system codes beginning with letters ‘A10’. Medication
use was determined by linkage to the Pharmaceutical
Benefits Scheme which includes details and information
on medicines subsidised by the Australian Government.
Plasma samples were obtained from all subjects (fasting,
at clinic visits) and stored at −80 °C. Fasting plasma
glucose was measured using an automated chemistry
analyser system (Olympus AU5400; Olympus Corp,
Tokyo, Japan). Glycated haemoglobin was measured
by high-performance liquid chromatography using a
spherical cation exchange gel (inter-assay coefficient
of variation [CV], 2 % at 6 % of total haemoglobin).
Predictor variables
We selected predictor variables from risk models that
could be used in routine clinical practice including
the Australian type 2 diabetes risk assessment tool
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(AUSDRISK) [19], Atherosclerosis Risk in Communities
(ARIC) [29], Cambridge risk score [21], FINDRISC [30],
Framingham Offspring Study [31], San Antonio Heart
Study [20], and QDScore [32].
Demographic information included age, country of
birth, and annual gross household income. Ethnicity was
classified into two groups using country of birth data
(‘Asia, Middle East, North Africa, Southern Europe’ or
‘Other’ [including Australia]). Income was classified into
eight ordinal groups. Additional data collected by self-
report included family history of diabetes, currently tak-
ing high blood pressure medication, doctor diagnosed
cardiovascular disease (NWAHS heart attack, stroke, an-
gina, or transient ischaemic attack; FAMAS angina, or
other heart conditions), current smoking status, and
leisure-time physical activity. Leisure-time physical activ-
ity data were derived from self-reported duration and
intensity of physical exercise (including walking) for re-
creation, sport or health/fitness during the past two
weeks, at the time of the interview. Total time spent
in leisure-time physical activity was multiplied by in-
tensity weights (3.3 for walking, 4.0 for moderate and
8.0 for vigorous intensity exercise) to compute meta-
bolic equivalent-min per week (MET-mins/wk). A MET-
mins/wk score of ≥540 is equivalent to 135 min or more
per week of at least moderate intensity physical activity.
Body weight, height and waist circumference (mean of
three measures) were taken using standard anthropomet-
ric assessments. BMI was computed as weight in kilo-
grams divided by height in metres squared. Standard
international cut-off points were used to define healthy
weight (BMI 18.50–24.99 kg/m2), overweight (BMI
25.00–29.99 kg/m2), and obese (BMI ≥30.00 kg/m2)
categories. Waist circumference risk categories were
classified using ethnic specific cut-off points for Asian
(low ≤90 cm, medium 90–100 cm, high >100 cm),
and Other (low ≤102 cm, medium 102–110 cm, and
high >110 cm) based on the AUSDRISK criteria [19].
Pre-diabetes was defined by IFG using FPG levels
5.6–6.9 mmol/L (100.9–124.3 mg/dL,), or HbA1c levels
5.7–6.4 % according to American Diabetes Association
criteria [28]. High blood pressure (≥140/90 mmHg) was
determined by the mean of two or three readings after
10 min of seated rest. Serum lipid concentrations were de-
termined enzymatically using a Hitachi 911 chemistry
analyser (Boehringer, Germany); (inter-assay CV was
6.7 % for HDL-C, and 3.0 % for triglycerides). Cut-off
points were used to classify low HDL-C (<1.0 mmol/L, or
38.6 mg/dL) and high triglycerides (>1.7 mmol/L, or
150.4 mg/dL) based on criteria proposed by the National
Cholesterol Education Program, Adult Treatment
Panel III [33]. Serum total testosterone was measured
by an API-5000 triple-quadrupole mass spectrometer
(Applied Biosystems/MDS SCIEX, Toronto, Ontario,
Canada). The inter-assay coefficients of variation (CV) for
serum total testosterone were 10.1 % at 0.43 nmol/L
(12.4 ng/dL), 11.1 % at 1.66 nmol/L (47.8 ng/dL), and 4 %
at 8.17 nmol/L (235.4 ng/dL) [34].
Statistical analyses
Predictor variables from previously validated risk models
were considered. Missing data on predictor variables
were replaced through multiple imputations with five
versions of the data set imputed using all predictor vari-
ables. Results for each predictor were individually tabu-
lated for men who developed T2D and men who did not
and Chi-square tests were used to confirm statistical sig-
nificance. Multivariable modelling was conducted using
logistic regression with developed T2D versus did not as
the dichotomous outcome. The goodness of fit of the
models was summarised using the Hosmer-Lemeshow
(HL) Chi-square statistic: with a statistically significant
(p < 0.05) HL statistic indicating poor fit. Akaike and
Bayesian information criteria (AIC and BIC) are pre-
sented as descriptive indicators of the relative quality
of competing statistical models: with smaller AICs
and BICs indicating preferred models. The Nagelkerke
R2 was monitored for sudden movement towards 1
which could indicate overfitting. The overall predict-
ive power of the models was summarised as area
under the receiver operating curve (AROC) and asso-
ciated 95 % confidence intervals. The statistical sig-
nificance of the difference between AROCs was tested
using the method by DeLong et al. (1988) [35]. Com-
peting cut-off points for defining low testosterone
levels were visually compared on sensitivity, specifi-
city, positive predictive power and age adjusted odds
ratios from logistic regressions. Finally starting with
all predictors in the model, a backwards stepwise se-
lection algorithm (likelihood ratio P-value to exclude
P > 0.25 and to re-enter P < 0.20) was applied to iden-
tify a minimal group of important independent pre-
dictors. AROCs were compared using MedCalc software
(http://www.medcalc.org/); all other analyses were con-
ducted using SPSS.
Results
The incidence rate of T2D was 8.9 % (147/1655) over a
median follow-up of 4.95 years (IQR 4.35-5.00). Table 1
shows baseline characteristics of participants in the
MAILES Stage 1 cohort by T2D status at follow-up, in-
cluding crude incidence and corresponding age-adjusted
odds ratios. The relative incidence of T2D was signifi-
cantly highest for older age and (after age-adjustment),
lowest income, family history of diabetes, pre-diabetes,
IFG, currently taking blood pressure medication, high
blood pressure, high triglycerides, low HDL-C, obese,
and high-risk waist circumference groups.
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Table 1 Baseline characteristics of participants in the MAILES cohort by T2D status at 5 years follow-up, crude incidence and
corresponding age-adjusted odds ratios





P % with T2D Age-adjusted odds ratio
(95 % CI)
Age (years)
35–44 20 377 5.0 1
45–54 34 449 7.0 1.43 (0.80,2.52) a
55–64 47 374 11.2 2.37 (1.38,4.08) a
≥65 46 308 <0.001 13.0 2.82 (1.63,4.86) a
Missing 0 (0.0 %) 0 (0.0 %)
Ethnicity/Country of birth
Asia, Middle East, North Africa, Southern Europe 15 119 11.1 0.83 (0.47,1.47)
Other (North West Europe, Americas, Oceania/Australia) 132 1387 0.329 8.7 1
Missing 0 (0.0 %) 2 (0.1 %)
Income (AUD)
Up to $12,000 15 72 17.1 2.89 (1.30,6.38)
$12,001 – $20,000 23 148 13.7 2.13 (1.03,4.39)
$20,001 – $30,000 24 193 11.5 1.82 (0.91,3.64)
$30,001 – $40,000 16 181 8.8 1.52 (0.74,3.13)
$40,001 – $50,000 13 188 6.5 1.16 (0.54,2.47)
$50,001 – $60,000 15 181 7.6 1.41 (0.68,2.92)
$60,001 – $80,000 18 225 8.0 1.54 (0.77,3.11)
More than $80,000 16 294 0.003 5.2 1
Missing 7 (4.8 %) 26 (1.7 %)
Family history of diabetes
Yes 55 410 11.9 1.80 (1.25,2.58)
No 91 1095 0.007 7.7 1
Missing 1 (0.6 %) 3 (0.2 %)
FPG (mean, mmol/L)
Mean (sd) 5.32 (0.71) 4.80 (0.60) <0.001b
Missing 0 (0.0 %) 10 (0.7 %)
HbA1c (mean, %)
Mean (sd) 5.87 (0.34) 5.49 (0.36) <0.001b
Missing 0 (0.0 %) 8 (0.5 %)
Pre-diabetes (FPG 5.6–6.9 mmol/L or HbA1c 5.7–6.4 %)
Yes 126 562 18.2 9.23 (5.72,14.90)
No 21 936 <0.001 2.2 1
Missing 0 (0.0 %) 10 (0.7 %)
Impaired fasting glucose (FPG 5.6–6.9 mmol/L)
Yes 59 142 28.7 5.63 (3.87,8.19)
No 88 1356 <0.001 6.1 1
Missing 0 (0.0 %) 10 (0.7 %)
Currently taking blood pressure medication
Yes 57 294 16.2 2.11 (1.43,3.11)
No 90 1209 <0.001 6.9 1
Missing 0 (0.0 %) 5 (0.3 %)
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Table 1 Baseline characteristics of participants in the MAILES cohort by T2D status at 5 years follow-up, crude incidence and
corresponding age-adjusted odds ratios (Continued)
High blood pressure (≥140/90 mmHg)
Yes 88 629 12.2 1.77 (1.24,2.53)
No 59 874 <0.001 6.3 1
Missing 0 (0.0 %) 5 (0.3 %)
Triglycerides (mean, mmol/L)
Mean (sd) 1.99 (1.36) 1.70 (1.32) 0.013b
Missing 0 (0.0 %) 7 (0.5 %)
High triglycerides (>1.7 mmol/L)
Yes 68 505 11.8 1.79 (1.27,2.54)
No 79 996 0.002 7.3 1
Missing 0 (0.0 %) 7 (0.5 %)
HDL-C (mean, mmol/L)
Mean (sd) 1.20 (0.31) 1.27 (0.30) 0.011b
Missing 0 (0.0 %) 7 (0.5 %)
Low HDL-C (<1.0 mmol/L)
Yes 30 193 13.4 1.84 (1.19,2.84)
No 117 1308 0.011 8.2 1
Missing 0 (0.0 %) 7 (0.5 %)
Diagnosed cardiovascular disease
Yes 18 104 14.7 1.41 (0.81,2.44)
No 129 1402 0.018 8.4 1
Missing 0 (0.0 %) 2 (0.1 %)
Total testosterone (mean, nmol/L)
Mean (sd) 15.0 (5.9) 17.7 (5.9) <0.001 b
Missing 10 (6.8 %) 146 (9.7 %)
Currently smoking
Yes 17 248 6.4 0.78 (0.46,1.32)
No 128 1257 0.136 9.4 1
Missing 2 (1.4 %) 3 (0.2 %)
Physically inactivity (<540 METs)
<540 METs 77 781 9.2 1.14 (0.81,1.61)
≥540 METs 62 665 0.754 8.5 1
missing 8 (5.4 %) 62 (4.1 %)
Body mass index (kg/m2)
Healthy weight 18.50–24.99 19 341 5.3 1
Overweight 25.00–29.99 69 768 8.2 1.57 (0.93,2.65)
Obese ≥30.00 59 399 <0.001 12.9 2.65 (1.54,456)
Missing 0 (0.0 %) 0 (0.0 %)
Waist circumference category
Low risk 65 925 6.5 1
Medium risk 39 361 9.7 1.42 (0.93,2.15)
High risk 42 215 <0.001 16.6 2.65 (1.74,4.02)
Missing 1 (0.7 %) 7 (0.5 %)
Notes: FPG fasting plasma glucose, IFG impaired fasting glucose, HbA1c glycated haemoglobin %, HDL-C high density lipoprotein cholesterol, METs metabolic equivalents of
leisure-time physical activity in the past week; Waist circumference risk categories were classified using ethnic specific cut-off points for Asian and Aboriginal (low ≤90 cm,
medium 90–100 cm, high >100 cm), and Other (low ≤102 cm, medium 102–110 cm, and high >110 cm); a not age-adjusted; b independent samples t-test
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Table 2 shows the added predictive value of low serum
total testosterone compared to current T2D risk models
in men over 5 years. Model 1 shows that variables from
the AUSDRISK [19] resulted in good performance for
predicting incident T2D. Model 2 shows additional vari-
ables from other current T2D risk models improved the
AROC statistic of Model 1 (net change in AROC was
0.051 [95 % CI: 0.013,0.089], P = 0.009). Model 3 shows
no evidence (no or very small changes in AROC and HL
χ2 statistics) of improvement to Model 2 after fitting
serum testosterone as a continuous variable. However, it
remained an independent predictor of incident T2D (OR
0.96 [95 % CI: 0.92,1.00], P = 0.032) with the Nagelkerke
R2 of 0.25.
Table 3 shows that a cut-off point of <16 nmol/L for
low serum testosterone, which classified about 43 % of
men, returned equal sensitivity (61.3 % [95 % CI:
52.6,69.4]) and specificity (58.3 % [95 % CI: 55.6,60.9) for
predicting T2D risk, with a PPV of 12.9 % (95 % CI:
10.4,15.8). Model 4 shows there was little evidence of
improvement to Model 2 after fitting low serum testos-
terone (<16 vs. ≥16 nmol/L) as a categorical variable
(OR 1.38 [95 % CI: 0.93,2.07,], P = 0.114). Model 5 shows
similar performance compared to Model 2 for predicting
T2D risk for variables retained using backwards selec-
tion; including family history of diabetes, blood pressure
medication, smoking status, waist circumference from
the AUSDRISK; and high blood pressure, low HDL-C,
pre-diabetes, high triglycerides and low serum testoster-
one (4/5 data sets). Finally, sensitivity analyses show
similar AROC statistics for Model 4 without imputation
(Model 6) and for Models 7 and 8 in the NWAHS and
FAMAS cohorts separately.
Discussion
The results of this study confirmed that serum testos-
terone predicts 5 year risk of developing T2D in men
(Model 3), independent of all risk factors from T2D
risk assessment models or tools applicable for use in
routine clinical practice, including the AUSDRISK
[19–21, 29–32]. We found that an age-adjusted serum
testosterone of <16 nmol/L, which was highly preva-
lent in the MAILES cohort (43 %), was optimal for
equalising sensitivity and specificity in predicting inci-
dent T2D and has a 12.9 % PPV, which is comparable
to the AUSDRISK (12.7 %) [19] and FINDRISC (13 %)
Table 2 Performance of risk models for predicting 5 year risk of T2D in men
Incidence (n/N) AROC (95 % CI) HL Chi-SQ statistic P for HL AIC BIC
Risk prediction models: variables
Model 1: Variables from AUSDRISK a 147/1655 0.76 (0.72,0.80) 5.29 0.726 895 960
Model 2: Model 1 with variables from other risk models b 147/1655 0.82 (0.79,0.86) 4.84 0.775 847 987
Model 3: Model 2 with total testosterone (continuous variable) 147/1655 0.82 (0.79,0.86) 4.45 0.815 844 990
Model 4: Model 2 with total testosterone (<16 vs ≥16 nmol/L) 147/1655 0.83 (0.79,0.86) 3.97 0.860 846 992
Model 5: Backwards selection modelc 147/1655 0.82 (0.78,0.85) 5.43 0.711 825 885
Sensitivity analyses
Model 6: Model 4 without imputation (15.5 % missing) 126/1399 0.82 (0.78,0.86) NA NA NA NA
Model 7: Model 4 for NWAHS cohort 62/820 0.79 (0.74,0.85) NA NA NA NA
Model 8: Model 4 for FAMAS cohort 85/835 0.84 (0.79,0.88) NA NA NA NA
Notes: AROC area under receiver operating characteristic curve (imputation with median AROC reported), HL Hosmer-Lemeshow, AIC Akaike information criterion;
Bayesian information criterion, NA not applicable because we are not fitting a new model - just testing the existing model; a Age, ethnicity/country of birth, family
history of diabetes, IFG instead of self reported high blood glucose, currently taking blood pressure medications, current smoking status, physical inactivity, waist
circumference category; b Pre-diabetes, BMI category, diagnosed cardiovascular disease, high blood pressure, high triglycerides, low HDL-C, income category;
c Backwards selection model started with all available variables included in Model 4, dropped if p > 0.25, re-entered if p < 0.20 (retained variables were family
history of diabetes, currently taking blood pressure medications, current smoking, waist circumference category, pre-diabetes, high blood pressure, low HDL-C low
serum testosterone <16 nmol/L); Net changes in AROC were: Model 5 vs Model 2, 0.0093 (95 % CI: −0.0032,0.0218, P = 0.1455)
Table 3 Sensitivity, specificity and positive predictive values for
serum total testosterone cut-off points for predicting 5 year risk
of T2D in men









value, % (95 % CI)
<10 vs ≥10 16.1 (10.5,23.5) 93.4 (91.9,94.6) 19.6 (13.0,28.4)
<11 vs ≥11 24.1 (17.4,32.3) 89.0 (87.2,90.6) 18.0 (12.9,24.5)
<12 vs ≥12 28.5 (21.3,36.9) 83.8 (81.8,85.7) 15.1 (11.0,20.1)
<13 vs ≥13 37.2 (29.2,45.9) 77.9 (75.6,80.1) 14.4 (11.1,18.7)
<14 vs ≥14 44.5 (36.1,53.2) 71.4 (68.9,73.8) 13.6 (10.6,17.1)
<15 vs ≥15 54.7 (46.0,63.2) 65.6 (63.0,68.1) 13.8 (11.0,17.0)
<16 vs ≥16 61.3 (52.6,69.4) 58.3 (55.6,60.9) 12.9 (10.4,15.8)
<17 vs ≥17 68.6 (60.0,76.1) 51.2 (48.6,53.9) 12.4 (10.2,15.0)
<18 vs ≥18 75.9 (67.7,82.6) 43.5 (40.9,46.2) 11.9 (9.9,14.3)
<19 vs ≥19 80.3 (72.4,86.4) 37.2 (34.7,39.9) 11.4 (9.5,13.6)
<20 vs ≥20 82.5 (74.9,88.2) 31.3 (28.8,33.8) 10.8 (9.0,12.8)
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[30] for optimal risk score cut-off points. This cut-off
point for low serum testosterone (<16 nmol/L) is higher
than that reported in a previous systematic review of pro-
spective cohort studies on T2D risk in men (7.4–
15.5 nmol/L]) [15], and also higher than that reported for
predicting T2D prevalence in men (<11 nmol/L) based on
the FAMAS [17].
While including serum testosterone does not improve
the performance of current risk models, it remained a
predictor of developing T2D after correction for all of
the other predictors (Model 3). This suggests that
screening for low serum testosterone would identify a
large group of men otherwise not apparent with current
T2D risk assessment tools, which might be clinically im-
portant for treatment decision making and resulting
prognosis. Research on mechanisms suggest that low
serum testosterone decreases insulin resistance indir-
ectly by promoting metabolically favourable changes in
body composition [36]; and directly by enhancing
catecholamine-induced lipolysis in vitro [37] and redu-
cing lipoprotein lipase activity and triglyceride uptake in
human abdominal adipose tissue in vivo [38]. Moreover,
endogenous testosterone levels correlate positively with
mitochondrial indices of increased insulin sensitivity in
human skeletal muscle [39], and has been shown to dir-
ectly regulate pathways responsible for skeletal muscle
glucose metabolism [40].
Evidence from short-term randomized controlled
trials (RCTs) suggests that testosterone supplementa-
tion therapy may improve glucose control in men
with, or at-risk of, low testosterone level. For in-
stance, we meta-analysed the results of relevant stud-
ies and found that testosterone therapy improved
FPG in 14 RCTs in 777 participants (standardised
mean difference was −0.2 [95 % CI: −0.4,-0.1]) [41–54];
and insulin resistance in nine RCTs in 589 partici-
pants (standardised mean difference was −0.3 [95 %
CI: −0.5,-0.1] for homeostasis assessment model of in-
sulin resistance [42–47, 49, 53, 54] over short and
medium terms. A recent and more relevant systematic
review of RCTs (placebo-controlled) found that tes-
tosterone therapy improved insulin resistance in men
with T2D and/or the metabolic syndrome (standardised
mean difference was −0.34 [95 % CI: −0.51,-0.16]), over
short terms [55]. In addition, evidence suggests the bene-
fits of testosterone therapy for glucose control may be
greatest when combined with lifestyle intervention [46].
This is an important therapeutic finding because there is
international consensus supporting the effectiveness of
lifestyle intervention in the prevention and management
of T2D [56].
Conversely, testosterone therapy has been associated
with serious adverse events in men. A systematic review
of 27 RCTs found that testosterone therapy vs. placebo
increased the risk of a cardiovascular-related event in
mainly older men (pooled odds ratio was 1.54 [95 % CI:
1.09, 2.18]) [57]. However, a more recent systematic re-
view of RCTs in mostly older men found there was an
increased cardiovascular risk associated with oral testos-
terone therapy (pooled relative risk was 2.20 [95 % CI:
1.45,3.55]), but not with intramuscular (pooled relative
risk was 0.66 [95 % CI: 0.28,1.56) or transdermal (gel or
patch) testosterone therapy (pooled relative risk was 1.27
[95 % CI: 0.62,2.62]) [58]. Further research is needed to
establish the safety of specific types of testosterone ther-
apies in specific populations.
Currently, we are undertaking a Phase IIIb multi-
centre randomized controlled trial (double-blinded
and placebo-controlled) to determine whether testos-
terone therapy (1000 mg testosterone undeconate)
combined with lifestyle intervention will reduce the
rate of T2D in men with both low testosterone and
pre-diabetes or newly diagnosed T2D more than life-
style intervention alone over two years (http://
www.t4dm.org.au/). Testosterone undecanoate is reg-
istered for use in Australia for the treatment of male
hypogonadism (Australian Registration Number AUST
R 106946). If testosterone undecanoate is shown to
be safe and effective pharmacotherapy for preventing
T2D in men, then screening for low serum testoster-
one additional to current T2D risk assessment models
(like the AUSDRISK in Australia) would identify a
large subgroup of distinct men who might benefit
from both targeted pharmacotherapy and lifestyle pre-
ventive interventions.
However, screening for low serum testosterone in
community-based patients should be applied only to
men suggestive of clinical presentations, otherwise
additional blood testing would potentially cause a
blowout in healthcare costs since serum testosterone
level of <16 nmol/L is highly prevalent in men aged
35 years and over [59]. Furthermore, treatment deci-
sions following confirmed screening positives will
need to consider not only the optimal cut-off point
for low testosterone, but also on the cost-effectiveness
of adjunctive testosterone therapy, which is currently
being investigated (http://www.t4dm.org.au/), as well
as treatment availability.
Important quality items of this study include the large
regionally representative sample of Australian men, pre-
cision of clinical measures, and the sufficient description
of dropouts and non-respondents [22]. Study limitations
include the reliance on a small number of self-report
measures, respondent compliance, residual confounding,
and misclassification of diseases and other factors poten-
tially resulting in bias. While there were only 147 inci-
dent cases, the ratio of 100 observations per predictor
variable, the relative stability of the AIC and BIC and the
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fact that the Nagelkerke R2 is much lower than 1 provide
no evidence of over-fitting. Further evidence from
prospective cohort studies is needed to confirm the
generalizability of these findings and the applicability of
screening for low serum testosterone in other male pop-
ulations and specific healthcare settings.
Conclusion
In conclusion, low serum testosterone predicts an in-
creased risk of developing T2D in men over 5 years inde-
pendent of current T2D risk models applicable for use in
routine clinical practice. Screening for low serum testos-
terone in addition to risk factors from current T2D risk
assessment models or tools, including the AUSDRISK,
would identify a large subgroup of distinct men who
might benefit from targeted preventive interventions.
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